Comparison of epitopes and neutralization potency of mAbs recognizing domain III of DENV E protein.

<p>*Potent neutralizing mAbs against DENV2 and DENV1 were defined by PRNT₅₀ ≤311 µg/ml and ≤590 µg/ml, respectively. Most of the potent neutralizing mAbs were generated by immunization of IFN-α/β R -/- C57BL/6 mice with DENV twice and booster with recombinant domain III <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001447#pntd.0001447-Shrestha1" target="_blank">[33]</a>, <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001447#pntd.0001447-SukupolviPetty2" target="_blank">[34]</a> , whereas most of the less potent neutralizing mAbs were generated by immunization of WT BALB/c mice <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001447#pntd.0001447-Gromowski1" target="_blank">[29]</a>, <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001447#pntd.0001447-Gromowski2" target="_blank">[30]</a>, <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001447#pntd.0001447-SukupolviPetty1" target="_blank">[32]</a>, <a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001447#pntd.0001447-Chen1" target="_blank">[38]</a>–<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0001447#pntd.0001447-Roehrig1" target="_blank">[42]</a>.